perenostobart   Click here for help

GtoPdb Ligand ID: 12103

Synonyms: SRF-617 | SRF617
Immunopharmacology Ligand
Compound class: Antibody
Comment: Perenostobart is a monoclonal antibody that targets ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1/CD39). Based on analysis using the amino acid (aa) sequences provided in the INN documentation and patented aa sequences (via NCBI Blast: protein), perenostobart would appear to map to Surface Oncology's clinical lead anti-CD39 mAb SRF617. Surface Oncology claim anti-CD39 mAbs in patent US10738128B2 [1]. SRF617 is a fully human mAb that was designed to inhibit the enzymatic activity of ENTPD1/CD39.
No information available.
Summary of Clinical Use Click here for help
SRF617 has progressed to clinical evaluation for anti-tumour potential.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04336098 Study of SRF617 in Patients With Advanced Solid Tumors Phase 1 Interventional Surface Oncology
NCT05177770 Study of SRF617 With AB928 (Etrumadenent) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer Phase 2 Interventional Surface Oncology